Arizona State University/Halberd Corp. Covid-19 R&D Program Rapid Diagnostic Test/Treatment
Halberd Corporation (OTC PINK: HALB) has announced a collaborative research project with Arizona State University to develop a rapid diagnostic test for Covid-19. The focus is on the coronavirus spike antigen, which is critical to the virus's contagiousness. Feasibility samples of an antibody conjugate are expected in four weeks, potentially enabling a quick testing method using saliva or blood. The company holds exclusive rights to relevant provisional patents for Covid-19 treatments.
- Collaboration with ASU aims to develop a rapid Covid-19 diagnostic test.
- Potential for a diagnostic test to provide results in minutes.
- Possibility of therapeutic applications for Covid-19 patients.
- Company holds exclusive rights to several Covid-19 treatment patents.
- Actual financial impact of the Covid-19 pandemic on company operations remains uncertain.
- Investor caution is advised due to risks associated with COVID-19 initiatives.
JACKSON CENTER, PA / ACCESSWIRE / September 24, 2020 / Halberd Corporation (OTC PINK:HALB) clarifies next steps in their unique research with Arizona State University. Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious - the spike antigen. ASU investigators have projected the production of the coronavirus spike antigen within the next two weeks.
The next steps for the ASU/Halberd program involve identification of an antibody conjugate which will fluoresce in the presence of the spike antigen to facilitate removal of the disease element via Halberd's patented extracorporeal treatments. Feasibility samples of the spike antigen antibody conjugate are expected to be available within four weeks.
Availability of the antibody conjugate will allow for the development of a molecule, to be patented, which can be used in a diagnostic capacity - in a rapid-results test for the coronavirus - and possibly in an extracorporeal treatment regimen.
William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, "With the successful creation of a fluorescent antibody, we hope to be able to create a rapid Covid-19 test using saliva or a drop of blood. We believe our approach will allow for accurate test results in a matter of minutes, and could be administered with minimal inconvenience/discomfort to those tested. Additionally, this approach could lead to a therapeutic application for coronavirus positive patients."
Dr. Reyes added, "Facilitating this ease of identification has profound ramifications for both diagnostic purposes as well as therapeutic use including facilitated eradication of targeted antigens."
Doctors Abdon Nanhay and Edson Brito further added "Our facilities in South America will be ideally suited for testing purposes. These initial tests could be the precursor to the commencement of FDA certification."
The details of the Halberd-ASU research contract can be viewed here.
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC
About Arizona State University.
Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona. It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.
About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here. The number of outstanding shares remains at 317,721,539.
The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com:
https://www.accesswire.com/607568/Arizona-State-UniversityHalberd-Corp-Covid-19-RD-Program-Rapid-Diagnostic-TestTreatment
FAQ
What is Halberd Corporation's focus in their Covid-19 research?
When will Halberd Corporation have feasibility samples for their Covid-19 test?
What is the expected outcome of the Halberd-ASU collaboration?
What patents does Halberd Corporation hold related to Covid-19 treatment?
What risks does Halberd Corporation highlight for investors?
